Related Experiment Video

Updated: Jul 13, 2026

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
06:38

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

Published on: April 12, 2017

The role of targeted therapy in metastatic renal cell carcinoma

Jaya Unnithan1, Brian I Rini

  • 1Department of Solid Tumor Oncology, Cleveland Clinic Taussig Cancer Center, Cleveland, OH, USA.

Thescientificworldjournal
|July 11, 2007
PubMed

Insights

Targeted therapies, including vascular endothelial growth factor receptor (VEGFR) and mammalian target of rapamycin (mTOR) inhibitors, show promise in treating advanced renal cell carcinoma (RCC). Clinical trials demonstrate their efficacy in managing this complex cancer.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Renal cell carcinoma (RCC) is characterized by high vascularity.
  • Advances in understanding RCC biology have led to new systemic therapies.
  • Key molecular targets include vascular endothelial growth factor (VEGF) and mammalian target of rapamycin (mTOR) pathways.

Purpose of the Study:

  • To describe the biological pathways implicated in RCC development.
  • To review clinical trial results for targeted therapies in metastatic RCC.
  • To provide an overview of current systemic treatment strategies for advanced RCC.

Main Methods:

  • Review of biological pathways in RCC.
  • Analysis of clinical trial data for targeted agents.
  • Description of orally available inhibitors like Sutent and sorafenib (VEGFR/PDGFR inhibitors) and temsirolimus (mTOR inhibitor).

Main Results:

  • VEGF/VEGFR and mTOR pathways are crucial in advanced RCC.
  • Orally available inhibitors targeting VEGFR and PDGFR (Sutent, sorafenib) are clinically utilized.
  • Temsirolimus, an mTOR inhibitor, induces cell cycle arrest and may impact VEGF production.

Conclusions:

  • Targeted therapies represent a significant advancement in treating advanced RCC.
  • Understanding the molecular pathways is key to developing effective treatments.
  • Ongoing research continues to refine systemic therapy options for RCC.

More Related Videos

Modeling Spontaneous Metastatic Renal Cell Carcinoma (mRCC) in Mice Following Nephrectomy11:27

Modeling Spontaneous Metastatic Renal Cell Carcinoma (mRCC) in Mice Following Nephrectomy

Published on: April 29, 2014

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Metastasis02:30

Metastasis

Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.